A new GHTC webinar—Achieving access to new innovations—discusses the challenges that hinder the development of and access to new global health technologies and the different approaches being taken in the R&D process to overcome these challenges and achieve widespread access.
Each year, the GHTC releases a policy report that includes recommendations for how US policymakers can continue to advance innovation and save lives around the world. A print summary version (2.2 MB PDF) of the report is also available.
The Drugs for Neglected Disease initiative and the Medicines for Malaria Venture have teamed up to ensure two treatments for malaria continue to reach the patients who need them most. The treatments—two fixed-dose artemisinin combination therapies known as ASAQ and ASMQ—were developed by DNDi and partners and launched in 2007 and 2008, respectively; going forward, MMV will work with those partners to ensure these drugs remain available and accessible in countries where they are most needed.